Working… Menu

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02824575
Recruitment Status : Recruiting
First Posted : July 6, 2016
Last Update Posted : December 11, 2020
Deciphera Pharmaceuticals LLC
Albert Einstein College of Medicine
Information provided by (Responsible Party):
Jesus Anampa Mesias, Montefiore Medical Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : December 2021